<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03948685</url>
  </required_header>
  <id_info>
    <org_study_id>4-2018-1061</org_study_id>
    <nct_id>NCT03948685</nct_id>
  </id_info>
  <brief_title>Carvedilol SR Study for Biomarkers From Blood and Urine and Safety of in Patients With Heart Failure With Preserved Ejection Fraction</brief_title>
  <official_title>Carvedilol SR Study for Biomarkers From Blood and Urine and Safety of in Patients With Heart Failure With Preserved Ejection Fraction : a Prospective, Randomized, Double Blind, Placebo-controlled, Multicenter, Pilot Trial (CAYMUS-HFpEF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Beta blockers have been used to reduce the mortality and heart failure rehospitalization in
      heart failure with reduced ejection fraction (HFrEF) patients in addition to ACEI/ARB, MRA,
      ivabradine and ARNI. However, the effective and safe medical therapy is not well established
      in heart failure with preserved ejection fraction (HFpEF) yet. Recent meta-analysis showed
      that beta blockers may also be beneficial for reducing the mortality and heart failure
      rehospitalization in HFpEF like HFrEF. However, the clinical effect and safety of carvedilol
      have been largely unknown in HFpEF. Therefore, CAYMUS HFpEF is the exploratory study to
      assess the change of surrogate markers (NTproBNP, hsTn) when treated with carvedilol SR vs.
      placebo in HFpEF patients
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Carvedilol SR vs. Placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Maximum NT-proBNP value change after Drug(Carvedilol SR or Placebo) administration.</measure>
    <time_frame>Baseline</time_frame>
    <description>The maximum NT-proBNP value change at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Maximum NT-proBNP value change after Drug(Carvedilol SR or Placebo) administration.</measure>
    <time_frame>8 weeks</time_frame>
    <description>The maximum NT-proBNP value change from baseline to 8 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Maximum NT-proBNP value change after Drug(Carvedilol SR or Placebo) administration.</measure>
    <time_frame>24 weeks</time_frame>
    <description>The maximum NT-proBNP value change from baseline to End of trial(24weeks).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The changes of maximum surrogate markers values(hsTn, hsCRP, sST2, Galectine-3, IGFBP7, Neprilysin, D-dimer, MMP-2, Cystatin C, NAG, NGAL, KIM-1, BUN, Creatinine, Chloride, Na, K, PICP and spondin-1) after Drug(Carvedilol SR or Placebo) administration.</measure>
    <time_frame>Baseline</time_frame>
    <description>the change of surrogate markers(hsTn, hsCRP etc) at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes of maximum surrogate markers values(hsTn, hsCRP, sST2, Galectine-3, IGFBP7, Neprilysin, D-dimer, MMP-2, Cystatin C, NAG, NGAL, KIM-1, BUN, Creatinine, Chloride, Na, K, PICP and spondin-1) after Drug(Carvedilol SR or Placebo) administration.</measure>
    <time_frame>8 weeks</time_frame>
    <description>the change of surrogate markers(hsTn, hsCRP etc) after 8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes of maximum surrogate markers values(hsTn, hsCRP, sST2, Galectine-3, IGFBP7, Neprilysin, D-dimer, MMP-2, Cystatin C, NAG, NGAL, KIM-1, BUN, Creatinine, Chloride, Na, K, PICP and spondin-1) after Drug(Carvedilol SR or Placebo) administration.</measure>
    <time_frame>16 weeks</time_frame>
    <description>the change of surrogate markers(hsTn, hsCRP etc) after 16 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes of maximum surrogate markers values(hsTn, hsCRP, sST2, Galectine-3, IGFBP7, Neprilysin, D-dimer, MMP-2, Cystatin C, NAG, NGAL, KIM-1, BUN, Creatinine, Chloride, Na, K, PICP and spondin-1) after Drug(Carvedilol SR or Placebo) administration.</measure>
    <time_frame>24 weeks</time_frame>
    <description>the change of surrogate markers(hsTn, hsCRP etc) from baseline to end of trial(24 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in degree of dyspnea using VAS questionnaire</measure>
    <time_frame>Baseline</time_frame>
    <description>the change of dyspnea at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in degree of dyspnea using VAS questionnaire</measure>
    <time_frame>8 weeks</time_frame>
    <description>the change of dyspnea after 8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in degree of dyspnea using VAS questionnaire</measure>
    <time_frame>16 weeks</time_frame>
    <description>the change of dyspnea after 16 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in degree of dyspnea using VAS questionnaire</measure>
    <time_frame>24 weeks</time_frame>
    <description>the change of dyspnea from baseline to end of trial(24 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of body weight</measure>
    <time_frame>Baseline</time_frame>
    <description>the change of body weight at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of body weight</measure>
    <time_frame>8 weeks</time_frame>
    <description>the change of body weight after 8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of body weight</measure>
    <time_frame>16 weeks</time_frame>
    <description>the change of body weight after 16 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of body weight</measure>
    <time_frame>24 weeks</time_frame>
    <description>the change of body weight from baseline to end of trial(24 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree</measure>
    <time_frame>Baseline</time_frame>
    <description>the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree during the tiral</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree</measure>
    <time_frame>8 weeks</time_frame>
    <description>the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree during the tiral</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree</measure>
    <time_frame>16 weeks</time_frame>
    <description>the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree during the tiral</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree</measure>
    <time_frame>24 weeks</time_frame>
    <description>the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree during the tiral</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the frequency of hypo/hyperkalemia and worsening kidney function</measure>
    <time_frame>Baseline</time_frame>
    <description>the frequency of hypo/hyperkalemia and worsening kidney function during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the frequency of hypo/hyperkalemia and worsening kidney function</measure>
    <time_frame>8 weeks</time_frame>
    <description>the frequency of hypo/hyperkalemia and worsening kidney function during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the frequency of hypo/hyperkalemia and worsening kidney function</measure>
    <time_frame>16 weeks</time_frame>
    <description>the frequency of hypo/hyperkalemia and worsening kidney function during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the frequency of hypo/hyperkalemia and worsening kidney function</measure>
    <time_frame>24 weeks</time_frame>
    <description>the frequency of hypo/hyperkalemia and worsening kidney function during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause hospitalization &amp; mortality</measure>
    <time_frame>Baseline</time_frame>
    <description>all-cause hospitalization &amp; mortality during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause hospitalization &amp; mortality</measure>
    <time_frame>8 weeks</time_frame>
    <description>all-cause hospitalization &amp; mortality during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause hospitalization &amp; mortality</measure>
    <time_frame>16 weeks</time_frame>
    <description>all-cause hospitalization &amp; mortality during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause hospitalization &amp; mortality</measure>
    <time_frame>24 weeks</time_frame>
    <description>all-cause hospitalization &amp; mortality during the trial</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Carvedilol SR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carvedilol SR 8mg, 16mg, 32mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol SR</intervention_name>
    <description>blood pressure, heart rate based titrated carvedilol SR for 24 weeks</description>
    <arm_group_label>Carvedilol SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of informed consent prior to any study specific procedure

          2. Male or female, aged ≥ 19 years

          3. Patients with chronic HF (Chronic Heart Failure) NYHA (New York Heart Association
             classification) class II-IV and preserved EF (Ejection Fraction)(LVEF (Left
             Ventricular Ejection Fraction) &gt; 40 %) and elevated NT-proBNP (N-terminal of the
             prohormone brain natriuretic peptide) &gt; 200 pg/ml for patients without AF, OR &gt; 600
             pg/ml for patients with AF, analysed at the Central laboratory at Visit 1

          4. Structural heart disease within 6 months prior to Visit 1 using echocardiagraphy

        Exclusion Criteria:

          1. Myocardial infarction, coronary artery bypass graft surgery or other major
             cardiovascular surgery, stroke or TIA (Transient Ischaemic Attack) in past 90 days
             prior to Visit 1

          2. Contraindication to beta blocker

          3. Heart transplant recipient or listed for heart transplant

          4. Hospitalization plan for PCI, coronary artery bypass graft surgery, other cardiac
             invasive interventions (e.g. catheter ablation, pacemaker, CRT, ICD implantation)

          5. Acute decompensated HF (Heart Failure)

          6. Symptomatic hypotension or systolic blood pressure &lt; 100 mmHg)

          7. Patients with CrCl &lt; 30 ml/min using creatinine-based CKD-EPI equations

          8. Elevated liver enzymes (3 times over upper reference limit) or liver cirrhosis

          9. Symptomatic bradycardia or heart rate &lt; 60/min

         10. Allergy, adverse drug reaction, hypersensitivity to carvedilol

         11. Life expectancy &lt; 6 months (e.g. metastatic malignancy)

         12. Pregnancy, or women of childbearing age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Seok-Min Kang, MD, Ph.D</last_name>
    <phone>82-2-2228-8450</phone>
    <email>smkang@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 3, 2019</study_first_submitted>
  <study_first_submitted_qc>May 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2019</study_first_posted>
  <last_update_submitted>May 19, 2019</last_update_submitted>
  <last_update_submitted_qc>May 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

